Dr. Reddy: 2Q PAT down 31% - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy: 2Q PAT down 31%

Oct 24, 2002

Dr. Reddy's, after reporting solid growth over the past year, has registered a decline in turnover. The drop in sales is primarily due to slowdown in fluoxetine sales, which has reflected across the income statement. The company has continued to show good growth in active pharma ingredients (API) business and branded formulations.

(Rs m) 2QFY02 2QFY03 Change 1HFY02 1HFY03 Change
Net Sales 4,739 4,037 -14.8% 7,375 7,387 0.2%
Other Income 204 167 -17.9% 290 334 15.2%
Expenditure 2,298 2,934 27.7% 4,280 5,346 24.9%
Operating Profit (EBDIT) 2,442 1,103 -54.8% 3,096 2,042 -34.1%
Operating Profit Margin (%) 51.5% 27.3%   42.0% 27.6%  
Interest 14 13 -8.4% 64 27 -58.1%
Depreciation 122 144 18.6% 234 281 20.0%
Profit before Tax 2,510 1,114 -55.6% 3,087 2,068 -33.0%
Extraordinary income (1,083) -   (1,083) -  
Tax (8) 122 -1677.9% 35 274 694.5%
Profit after Tax/(Loss) 1,434 992 -30.8% 1,969 1,793 -8.9%
Net profit margin (%) 30.3% 24.6%   26.7% 24.3%  
No. of Shares (eoy) (m) 38.3 76.5   38.3 76.5  
Fully Diluted Earnings per share* 75.0 51.9   51.5 46.9  
P/E Ratio         15.5  

In our earlier reports, we had indicated that sales from fluoxetine business are expected to decline. Adjusting for the same, sales in the half-year period have increased by 22% YoY. The API business is likely to have continued to performed well on the back of Tizanidine and Doxazosin. API exports are expected to catapult in the future considering the fact that the company has filed 3 DMF's (Drug Master Filings) in 4QFY02 and is likely to have made more filings last quarter.

In branded formulations, the company reported a overall 14% growth including both domestic and international business. The growth in the domestic market could have been facilitated by dental products. It may be recalled that the company acquired 6 dental brands in India from a local Indian company (Groupe Pharma) last year, which has added to domestic formulations sales in the current year.

As mentioned earlier, financials are reflecting the effect of decline in fluoxetine sales. Marketing exclusivity for fluoxetine expired in January '02 leading to sharp price erosion (almost 80%), as two other competitors have entered the market. That said, with revenues from new businesses supporting organisational expansion and increased R&D expense, a similar buffer has not been present in quarter ended September '02 leading to drop in margins. R&D expense for the quarter has almost doubled from 4.5% to 8.6% of net sales.

At Rs 726, the scrip is trading on a multiple of 15.5x 1HFY03 annualised stand-alone earnings, as compared to 20.2x 1QFY03 annualised stand-alone earnings. It may be recalled that the company received a major setback in 2Q with suspension of clinical trials for the outlicensed anti-diabetic molecule (Ragaglitazar). Also, there were concerns that the company delayed disclosing the Ragaglitazar setback. We had mentioned that moving towards a research oriented business model could lead to lumpiness in earnings before a steady drug pipeline is built.


Equitymaster requests your view! Post a comment on "Dr. Reddy: 2Q PAT down 31%". Click here!

  

More Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 29, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS